A bioethicist’s take on child cancer treatment that uses gene therapy – Catholic News Agency
Catholic News Agency |
A bioethicist’s take on child cancer treatment that uses gene therapy
Catholic News Agency A genetic modification therapy designed for treating pediatric leukemia has drawn both praise and caution from a Catholic bioethicist, after recently being approved by the Food and Drug Administration. While a “promising” use of gene modification … |
Bloomberg |
Hurricane Irma Churns Toward Florida
Bloomberg Hurricane Irma became the most powerful storm to form in the open Atlantic Ocean, as it churns toward Florida with the prospect of property losses that could surpass Hurricane Katrina. Bloomberg’s Shunondo Basu reports on “What’d You Miss?” (Source: … |
|
Immunotherapy Initiative Launched in Israel to Combat Cancer
Jewish Link of New Jersey (l-r): Consul General of Israel in New York Dani Dayan, cancer researcher Prof. Yosef Yarden of Israel’s Weizmann Institute and Israel Cancer Research Fund President Rob Densen at the consul general’s residence. (Credit: Perry Bindelglass). |
SelectScience |
Product News: Improved Stem Cell Growth Performance with Xeno-Free Cell Culture Medium
SelectScience StemFit® Basic02 is a xeno-free, defined medium for human pluripotent stem cell (hiPSC) culture that offers an effective solution for regenerative medicine research. This medium has been proven to effectively maintain Induced Pluripotent Stem (iPS) and … |
|
Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR Summit
Markets Insider SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the … |
|
Poseida Therapeutics Presents Novel BCMA-Specific CAR–T Therapy at CAR-TCR Summit
Markets Insider SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the … |